MedCity News
AUGUST 1, 2024
Here is a list of some of the biggest funding rounds from health tech companies that were announced in July. The post 5 Notable Health Tech Funding Announcements in July appeared first on MedCity News.
Fierce Pharma
AUGUST 2, 2024
Adaptimmune has won accelerated FDA approval | Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma which becomes the first engineered cell therapy for a solid tumor and the first new treatment in the indication in more than a decade.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 30, 2024
Japanese researchers have developed a new method for photoisomerisation of E -cinnamamides to Z -cinnamamides. The approach uses a recycling photoreactor coupled with a high-performance liquid chromatography (HPLC) system. As organic compounds, many Z -alkenes “cannot be prepared through conventional methods involving thermodynamic methods”. On the other hand, “photoisomerisation can offer good yields”, they noted.
pharmaphorum
JULY 31, 2024
Vertex has filed for FDA approval of its non-opioid pain drug suzetrigine, starting the clock ticking on a review that should be completed early next year
MedCity News
JULY 30, 2024
Humana is leasing clinical space at 23 Walmart Supercenter retail stores. The move is logical for the insurer as it builds out its senior primary care business, experts say. The post Analysis: Humana is Boldly Going Where Walmart Stumbled appeared first on MedCity News.
Fierce Pharma
AUGUST 2, 2024
As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. | As of mid-July, around 20 patients completed the first step of Casgevy treatment by having their cells collected, up from five patients during the first quarter.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaVoice
AUGUST 1, 2024
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
MedCity News
JULY 29, 2024
As the FDA stakes its claim as the primary regulator of AI in healthcare, it must navigate the delicate balance between fostering innovation and ensuring safety and responsibility. The post Enabling Clinical Trial Innovation Through AI Regulation at FDA appeared first on MedCity News.
Fierce Pharma
JULY 31, 2024
Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more workers at the site. | Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more at the site, according to a state Worker Adjustment and Retraining Notification.
Pharmaceutical Technology
JULY 31, 2024
Gene therapy research is expensive. Biotechs invest millions of dollars in early research to develop therapies for conditions that might be rare. But when funds are limited and the market potential is dim, such programs are often abandoned by companies, leaving patients and investigators in a bind.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Quantified
JULY 30, 2024
The Power of Storytelling in Sales When was the last time you got lost in a story? Whether in a book, podcast, or movie, a well-told story has a powerful impact on its audience. When messages delivered as stories can be up to 22 times more memorable than mere facts. Stories engage multiple parts of our brains, enhancing focus and retention. Your Brain on Stories Neurological Engagement: Stories activate multiple brain areas, including motor cortexes, emotion, and visual processing centers, makin
MedCity News
JULY 31, 2024
AIRNA’s therapy for alpha1 antitrypsin deficiency, or AATD, edits RNA to address the underlying cause of this rare inherited disease. Wave Life Sciences and Korro Bio are both further along in the development of RNA-editing therapies for AATD, but AIRNA claims its therapy could be best in class. The post Biotech Startup AIRNA Adds $60M to Advance RNA-Editing Therapy for Rare Protein Deficiency appeared first on MedCity News.
Fierce Pharma
JULY 30, 2024
For more than a year after Pfizer’s COVID product sales peaked at the end of 2022, the company’s quarterly revenues showed year-over-year declines. | For the first time since its sales peaked during the pandemic, Pfizer registered year-over-year revenue growth during the second quarter of 2024. And while the busy has been busy trimming operating expenses, it did add $1 billion to its total revenue projection for the year.
Pharmaceutical Commerce
AUGUST 2, 2024
In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
pharmaphorum
AUGUST 2, 2024
Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on cardiovascular outcomes with the drug.
MedCity News
JULY 30, 2024
Empathy gets rationed when a high-volume practice is valued over a high-quality practice by administrators who aren’t seeing the patients in clinic — but patients rely on surgeons who can embrace the complex conditions. The post Spinal Surgery in The Setting of Complex Medical Conditions appeared first on MedCity News.
Fierce Pharma
JULY 29, 2024
Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition. | Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition.
Impetus Digital
AUGUST 2, 2024
A version of this article was previously published on PharmaPhorum. Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s remarkable to see the progress made in the technology compared to only a few months ago and there are no signs of the progress slowing down. The pharmaceutical industry has numerous use cases for AI.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JULY 29, 2024
Otsuka has teamed up with one of the innovation arms of the NHS to explore how a digital therapeutic (DTx) for major depressive disorder (MDD) could be deployed within the health service.The alliance with Health Innovation Oxford & Thames Valley (Oxford HIN) is focusing on Care for MDD, an app-based DTx that has been co-developed by Otsuka and digital health specialist Click Therapeutics.
MedCity News
AUGUST 1, 2024
Healthcare organizations can significantly improve their resilience against ransomware attacks by implementing proactive protection, continuous monitoring, and rapid recovery strategies. Proactive protection, continuous monitoring, and rapid recovery strategies are key. The post Nearly Every Large Healthcare Organization Uses Microsoft Active Directory: Here’s How to Secure It to Safeguard Against Escalating Ransomware Attacks appeared first on MedCity News.
Fierce Pharma
AUGUST 1, 2024
Like clockwork, another lawsuit challenging the constitutionality of the Inflation Reduction Act's (IRA's) price-setting measures has been shot down in the courts. | The ruling from the New Jersey federal court marks the latest in a string of rejections as various drugmakers have taken to the courts to fight the drug pricing legislation.
Pharmaceutical Technology
AUGUST 1, 2024
The UK NICE has recommended BeiGene’s Zanubrutinib for marginal zone lymphoma (MZL) for use on the National Health Service (NHS).
Pharmaceutical Commerce
JULY 29, 2024
A cohort study investigates whether or not the prevalence of these types of illnesses can vary among individuals who are COVID-positive versus negative.
MedCity News
AUGUST 1, 2024
Huma has spent 10 years perfecting its technology stack and now it wants others to build off of its expertise, says the company’s chief medical officer. The post Huma’s Evolution From Patient Monitoring Apps to Cloud Platform With AI Chops appeared first on MedCity News.
Fierce Pharma
JULY 29, 2024
Suboxone maker Indivior has spent years dealing with allegations related to its role in the United States opioid epidemic, inking several settlements over that span and even witnessing its former C | More than a dozen states linked up on the agreement after accusing Indivior of fueling the opioid epidemic with its opioid addiction treatment Suboxone.
pharmaphorum
JULY 31, 2024
Patient advocacy group APIC has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmaVoice
JULY 31, 2024
The U.S. government will demand payment from Big Pharma to make up for dozens of drugs with prices that rose faster than the rate of inflation.
MedCity News
AUGUST 2, 2024
Many medtech products, very often too technical and scientific, emphasize features at the expense of processes and their interactions. While the approach to patient and treatment safety is crucial, there is a notable shift towards processes centered around patients and healthcare professionals. The post Beyond Engineering: Integrating UX for Safer and More Efficient Medical Products appeared first on MedCity News.
Fierce Pharma
AUGUST 1, 2024
Like many other biopharma companies, Kyowa Kirin is in restructuring mode. | Kyowa Kirin is planning “a significant reduction” in its small molecule drug discovery research activities and will trim certain manufacturing roles. The company is also divesting its Chinese operations as part of a larger restructuring in the Asia-Pacific region.
pharmaphorum
JULY 30, 2024
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ethan Drower, co-founder and CEO of Cite Medical Solutions, a company providing full Clinical Evaluation Report (CER) services and industry literature review for European Union Medical Device Regulation (or EU MDR) processes.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
109 
Let's personalize your content